|
Q3 2022
|
1 |
21,360 |
TXG
|
13F-HR
|
11/14/2022 |
000110465922117989 |
|
Q2 2022
|
1 |
33,938 |
TXG
|
13F-HR
|
8/12/2022 |
000110465922089753 |
|
Q1 2022
|
2 |
57,218 |
TXG, EPZM
|
13F-HR
|
5/13/2022 |
000110465922059927 |
|
Q4 2021
|
2 |
112,079 |
TXG, EPZM
|
13F-HR
|
2/11/2022 |
000110465922020346 |
|
Q3 2021
|
4 |
127,826 |
TXG, NVAX, XLRN, EPZM
|
13F-HR
|
11/12/2021 |
000110465921137694 |
|
Q2 2021
|
4 |
165,887 |
TXG, NVAX, EPZM, XLRN
|
13F-HR
|
8/16/2021 |
000110465921105284 |
|
Q1 2021
|
4 |
198,262 |
TXG, NVAX, XLRN, EPZM
|
13F-HR
|
5/17/2021 |
000110465921067097 |
|
Q4 2020
|
4 |
190,084 |
TXG, NVAX, EPZM, XLRN
|
13F-HR
|
2/16/2021 |
000110465921023071 |
|
Q3 2020
|
4 |
355,166 |
TXG, NVAX, EPZM, XLRN
|
13F-HR
|
11/13/2020 |
000110465920124777 |
|
Q2 2020
|
3 |
317,262 |
TXG, EPZM, XLRN
|
13F-HR
|
8/13/2020 |
000110465920094438 |
|
Q1 2020
|
2 |
361,447 |
TXG, XLRN
|
13F-HR
|
5/14/2020 |
000110465920061240 |
|
Q4 2019
|
2 |
552,123 |
TXG, XLRN
|
13F-HR
|
2/5/2020 |
000110465920010866 |
|
Q3 2015
|
3 |
9,379 |
XLRN, BDSI, Orexigen Therapeutics, Inc.
|
13F-HR
|
11/13/2015 |
000114420415065110 |
|
Q2 2015
|
3 |
15,149 |
Orexigen Therapeutics, Inc., XLRN, BDSI
|
13F-HR
|
8/14/2015 |
000114420415049190 |
|
Q1 2015
|
4 |
21,737 |
Orexigen Therapeutics, Inc., BDSI, XLRN, Ignyta, Inc.
|
13F-HR
|
5/5/2015 |
000114420415027505 |
|
Q4 2014
|
6 |
67,901 |
KPTI, XNCR, BDSI, Orexigen Therapeutics, Inc.
|
13F-HR
|
2/11/2015 |
000114420415008028 |
|
Q3 2014
|
8 |
104,426 |
KPTI, AMBI, BDSI, XNCR
|
13F-HR
|
11/10/2014 |
000114420414066347 |
|
Q2 2014
|
8 |
119,290 |
KPTI, AMBI, XNCR, ACELRX Pharmaceuticals, Inc.
|
13F-HR
|
8/11/2014 |
000114420414048394 |
|
Q1 2014
|
11 |
142,352 |
KPTI, KERX, AMBI, ACELRX Pharmaceuticals, Inc.
|
13F-HR
|
5/15/2014 |
000114420414030644 |
|
Q4 2013
|
9 |
102,940 |
KPTI, AMBI, KERX, ACELRX Pharmaceuticals, Inc.
|
13F-HR
|
2/14/2014 |
000114420414009003 |